|
1
|
Roller JF, Veeramachaneni NK and Zhang J:
Exploring the Evolving scope of neoadjuvant immunotherapy in NSCLC.
Cancers (Basel). 14(741)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Li MSC, Mok KKS and Mok TSK: Developments
in targeted therapy & immunotherapy-how non-small cell lung
cancer management will change in the next decade: A narrative
review. Ann Transl Med. 30(358)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Schoenfeld AJ, Lee SM, Doger de Spéville
B, Gettinger SN, Häfliger S, Sukari A, Papa S, Rodríguez-Moreno JF,
Graf Finckenstein F, Fiaz R, et al: Lifileucel, an autologous
tumor-infiltrating lymphocyte monotherapy, in patients with
advanced non-small cell lung cancer resistant to immune checkpoint
inhibitors. Cancer Discov. 14:1389–1402. 2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen
L and Zhou J: The progress and challenge of anti-PD-1/PD-L1
immunotherapy in treating non-small cell lung cancer. Ther Adv Med
Oncol. 13(1758835921992968)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yin J, Wu Y, Yang X, Gan L and Xue J:
Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy
in non-small-cell lung cancer: Occurrence and mechanism. Front
Immunol. 13(830631)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhao Z, Wang X, Qu J, Zuo W, Tang Y, Zhu H
and Chen X: Immune-related adverse events associated with outcomes
in patients with NSCLC treated with anti-PD-1 inhibitors: A
systematic review and meta-analysis. Front Oncol.
11(708195)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang Q, Wang W, Yuan Q, Li L, Wang YC,
Chi CZ and Xu CH: Correlation between immune-related adverse events
and the efficacy of PD-1/PD-L1 inhibitors in the treatment of
non-small cell lung cancer: Systematic review and meta-analysis.
Cancer Chemother Pharmacol. 89:1–9. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Xie X, Wang L, Li Y, Xu Y, Wu J, Lin X,
Lin W, Mai Q, Chen Z, Zhang J, et al: Multi-organ immune-related
adverse event is a risk factor of immune checkpoint
inhibitor-associated myocarditis in cancer patients: A multi-center
study. Front Immunol. 13(879900)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhou YW, Zhu YJ, Wang MN, Xie Y, Chen CY,
Zhang T, Xia F, Ding ZY and Liu JY: Immune checkpoint
inhibitor-associated cardiotoxicity: Current understanding on its
mechanism, diagnosis and management. Front Pharmacol.
10(1350)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen X, Jiang A, Zhang R, Fu X, Liu N, Shi
C, Wang J, Zheng X, Tian T, Liang X, et al: Immune checkpoint
inhibitor-associated cardiotoxicity in solid tumors: Real-world
incidence, risk factors, and prognostic analysis. Front Cardiovasc
Med. 9(882167)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Moslehi J, Lichtman AH, Sharpe AH,
Galluzzi L and Kitsis RN: Immune checkpoint inhibitor-associated
myocarditis: Manifestations and mechanisms. J Clin Invest.
131(e145186)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen Y, Jia Y, Liu Q, Shen Y, Zhu H, Dong
X, Huang J, Lu J and Yin Q: Myocarditis related to immune
checkpoint inhibitors treatment: Two case reports and literature
review. Ann Palliat Med. 10:8512–8517. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Coustal C, Vanoverschelde J, Quantin X,
Lesage C, Michot JM, Lappara A, Ederhy S, Assenat E, Faure M, Issa
N, et al: Prognosis of immune checkpoint inhibitors-induced
myocarditis: A case series. J Immunother Cancer.
11(e004792)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang D, Bauersachs J and Berliner D:
Immune checkpoint inhibitor associated myocarditis and
cardiomyopathy: A translational review. Biology (Basel).
12(472)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jiménez-Alejandre R, Ruiz-Fernández I and
Martín P: Pathophysiology of immune checkpoint inhibitor-induced
myocarditis. Cancers (Basel). 14(4494)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gong J, Neilan TG and Zlotoff DA:
Mediators and mechanisms of immune checkpoint inhibitor-associated
myocarditis: Insights from mouse and human. Immunol Rev. 318:70–80.
2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Postow MA, Sidlow R and Hellmann MD:
Immune-related adverse events associated with immune checkpoint
blockade. N Engl J Med. 378:158–168. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liu X, Wu W, Fang L, Liu Y and Chen W:
TNF-α inhibitors and other biologic agents for the treatment of
immune checkpoint inhibitor-induced myocarditis. Front Immunol.
13(922782)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang J, Zhou T, Sun Z, Ye T, Zhou S, Li J,
Liu Y, Kong L, Tang J, Liu D and Xing HR: Zeb1 regulates the
symmetric division of mouse lewis lung carcinoma stem cells through
numb mediated by miR-31. Int J Biol Sci. 14:1399–1410.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
National Research Council (USA): Guide for
the care and use of laboratory animals, 8th edition. National
Academies Press, Washington, DC, pp11-123, 2011.
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xu L, Chen YK, Xiong L, Shen Y, Zhou Z,
Wang S and Xu X: A review of immune checkpoint inhibitor-associated
myocarditis: Epidemiology, pathogenesis, and biomarkers. Hum Vaccin
Immunother. 21(2512645)2025.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Al-Kindi SG and Oliveira GH: Reporting of
immune checkpoint inhibitor-associated myocarditis. Lancet.
392:382–383. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sun Z, Shen K, Xie Y, Hu B, He P, Lu Y and
Xue H: Shiquan Yuzhen Decoction inhibits angiogenesis and tumor
apoptosis caused by non-small cell lung cancer and promotes immune
response. Am J Transl Res. 13:7492–7507. 2021.PubMed/NCBI
|
|
26
|
Cui Y, Luo Y, Qian Q, Tian J, Fang Z, Wang
X, Zeng Y, Wu J and Li Y: Sanguinarine regulates tumor-associated
macrophages to prevent lung cancer angiogenesis through the
WNT/β-catenin pathway. Front Oncol. 12(732860)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huang F, Cao Y, Wang C, Lan R, Wu B, Xie
X, Hong J, Fu L and Wu G: PNMA5 promotes bone metastasis of
non-small-cell lung cancer as a target of BMP2 signaling. Front
Cell Dev Biol. 9(678931)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chan YP, Chuang CH, Lee I and Yang NC:
Lycopene in combination with sorafenib additively inhibits tumor
metastasis in mice xenografted with lewis lung carcinoma cells.
Front Nutr. 9(886988)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Han N, Yang ZY, Xie ZX, Xu HZ, Yu TT, Li
QR, Li LG, Peng XC, Yang XX, Hu J, et al: Dihydroartemisinin
elicits immunogenic death through ferroptosis-triggered ER stress
and DNA damage for lung cancer immunotherapy. Phytomedicine.
112(154682)2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang P, Fang X, Yin T, Tian H, Yu J and
Teng F: Efficacy and safety of anti-PD-1 plus anlotinib in patients
with advanced non-small-cell lung cancer after previous systemic
treatment failure-A retrospective study. Front Oncol.
11(628124)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Patel RP, Parikh R, Gunturu KS, Tariq RZ,
Dani SS, Ganatra S and Nohria A: Cardiotoxicity of immune
checkpoint inhibitors. Curr Oncol Rep. 23(79)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nishikawa T, Inoue T, Otsuka T, Kuno I,
Kukita Y, Nakamura H, Ikeda Y, Yasui T, Shioyama W, Oka T, et al:
Prevalence and characteristics of immune checkpoint
inhibitor-related myocardial damage: A prospective observational
study. PLoS One. 17(e0275865)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wu Y, Xu Y and Xu L: Drug therapy for
myocarditis induced by immune checkpoint inhibitors. Front
Pharmacol. 14(1161243)2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ali A, Caldwell R, Pina G, Beinart N,
Jensen G, Yusuf SW, Koutroumpakis E, Hamzeh I, Khalaf S, Iliescu C,
et al: Elevated IL-6 and tumor necrosis factor-α in immune
checkpoint inhibitor myocarditis. Diseases. 12(88)2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Johnson DB, Balko JM, Compton ML, Chalkias
S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et
al: Fulminant myocarditis with combination immune checkpoint
blockade. N Engl J Med. 375:1749–1755. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Naidoo J, Cottrell TR, Lipson EJ, Forde
PM, Illei PB, Yarmus LB, Voong KR, Feller-Kopman D, Lee H, Riemer
J, et al: Chronic immune checkpoint inhibitor pneumonitis. J
Immunother Cancer. 8(e000840)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Suresh K, Naidoo J, Zhong Q, Xiong Y,
Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM,
et al: The alveolar immune cell landscape is dysregulated in
checkpoint inhibitor pneumonitis. J Clin Invest. 129:4305–4315.
2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yang K, Li J, Sun Z, Zhao L and Bai C:
Retreatment with immune checkpoint inhibitors in solid tumors: A
systematic review. Ther Adv Med Oncol.
12(1758835920975353)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH,
Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG, et al: Hyperprogressive
disease during PD-1/PD-L1 blockade in patients with non-small-cell
lung cancer. Ann Oncol. 30:1104–1113. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Heckmann MB, Finke D, Sauerbrey L, Frey N
and Lehmann LH: Increased expression of human endogenous retrovirus
K in endomyocardial biopsies from patients with cardiomyopathy-a
transcriptomics meta-analysis. BMC Genomics. 25(707)2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhang Y, Sun X, Jin Y, Chen K, Zhang L,
Gao X, Li M, Yuan Z, Jia J, Sun A and Ge J: Mitochondrial
transplantation augments the reparative capacity of macrophages
following myocardial injury. Adv Sci (Weinh).
12(e06337)2025.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kim H, Ahn HS, Hwang N, Huh Y, Bu S, Seo
KJ, Kwon SH, Lee HK, Kim JW, Yoon BK and Fang S: Epigenomic
landscape exhibits interferon signaling suppression in the patient
of myocarditis after BNT162b2 vaccination. Sci Rep.
13(8926)2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Patel T, Kelleman M, West Z, Peter A, Dove
M, Butto A and Oster ME: Comparison of multisystem inflammatory
syndrome in children-related myocarditis, classic viral
myocarditis, and COVID-19 vaccine-related myocarditis in children.
J Am Heart Assoc. 11(e024393)2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wang X, Chen J, Shen Y, Zhang H, Xu Y,
Zhang J and Cheng L: Baricitinib protects ICIs-related myocarditis
by targeting JAK1/STAT3 to regulate macrophage polarization.
Cytokine. 179(156620)2024.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Nishikawa T, Tamiya M, Ohta-Ogo K, Ikeda
Y, Hatakeyama K, Honma K, Yasui T, Shioyama W, Oka T, Inoue T, et
al: A case of lung cancer with very-late-onset immune checkpoint
inhibitor-related myocarditis. CJC Open. 4:651–655. 2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Nishikawa T, Kunimasa K, Ohta-Ogo K, Ikeda
Y, Yasui T, Shioyama W, Oka T, Honma K, Hatakeyama K, Kumagai T and
Fujita M: Sinus node dysfunction co-occurring with immune
checkpoint inhibitor-associated myocarditis. Intern Med.
61:2161–2165. 2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Flippe L, Bézie S, Anegon I and
Guillonneau C: Future prospects for CD8+ regulatory T
cells in immune tolerance. Immunol Rev. 292:209–224.
2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Valaperti A, Nishii M, Liu Y, Naito K,
Chan M, Zhang L, Skurk C, Schultheiss HP, Wells GA, Eriksson U and
Liu PP: Innate immune interleukin-1 receptor-associated kinase 4
exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte
migration and impairing interferon production. Circulation.
128:1542–1554. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Lin W, Wang Y, Li M, Feng J, Yue Y, Yu J,
Hu Y and Suo Y: Tumor treating fields enhance anti-PD therapy by
improving CCL2/8 and CXCL9/CXCL10 expression through inducing
immunogenic cell death in NSCLC models. BMC Cancer.
25(489)2025.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Tan H, Shah NUH, He B, Liu T, Li T, Liu M,
Gu Y, Zhi C, Ou Y, Huang J, et al: Intratumoral delivery of
PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid
tumors: A proof-of-concept treatment strategy. Front Immunol.
16(1669924)2025.PubMed/NCBI View Article : Google Scholar
|
